Pierre Fouret, MD, PhD, Institut Gustave Roussy, Université Pierre et Marie Curie, Paris, France: Speaking at ASCO 2009: Lung Cancer Patients Lacking MSH2 DNA Repair Protein Fare Better with Chemotherapy: An analysis from the International Adjuvant Lung Trial (IALT) reports that tumor levels of the MSH2 protein predict long-term response to cisplatin-based chemotherapy among patients with surgically removed non-small cell lung cancer (NSCLC). MSH2 is a protein that cancer cells use to repair DNA damaged by cisplatin. Researchers found that patients with no or low levels of the MSH2 protein respond better to treatment than patients with high levels.